COBRE renewal expands nanotechnology research
Tatiana Bronich, Ph.D.
The grant, which will be awarded over five years, will fund the continuation of an Institutional Development Award to the Centers of Biomedical Research Excellence (COBRE).
UNMC researcher Tatiana Bronich, Ph.D., is the principal investigator on the grant. Dr. Bronich is the Parke-Davis Professor in Pharmaceutics, UNMC College of Pharmacy, and the co-director of the Center for Drug Delivery and Nanomedicine.
"Dr. Bronich has done a great job, not only in mentoring faculty actively involved in this COBRE, but in actively engaging other faculty, including clinical faculty, to identify new opportunities to extend this work into clinical care." Jennifer Larsen, M.D.
Jennifer Larsen, M.D.
Nanomedicine uses nanomaterials, small polymeric particles, to deliver drugs safely to disease sites, such as cancer tumors.
"This will further and solidify our efforts in the areas of drug delivery and nanomedicine," Dr. Bronich said.
"It allows us to continue our truly interdisciplinary research at the university."
In addition, the grant will support two research core facilities: the bioimaging core, directed by Michael Boska, Ph.D., radiology department; and the nanomaterials core, co-directed by Dr. Bronich and Dong Wang, Ph.D., pharmaceutical sciences.
The Nanomedicine COBRE provides UNMC with unique expertise and resources, said Jennifer Larsen, M.D., vice chancellor for research.
"Dr. Bronich has done a great job, not only in mentoring faculty actively involved in this COBRE, but in actively engaging other faculty, including clinical faculty, to identify new opportunities to extend this work into clinical care," Dr. Larsen said.
The renewal of the Nebraska Center for Nanomedicine grant is a significant accomplishment, said Courtney Fletcher, Pharm.D., dean of the College of Pharmacy.
"This grant was first funded in 2008, with the scientific mission to improve drug delivery, through basic and applied advances in nanotechnology, in order to advance treatment of human diseases," he said. "This five-year renewal provides the strongest evidence possible that Dr. Bronich and her team of scientists have made considerable progress on this mission -- and most importantly, has laid out a compelling plan for their future work."
Dr. Fletcher said the renewal also affirms that the drug delivery program at the College of Pharmacy and UNMC is both a national and international leader in this area of work -- "work that is fundamental to advancing the efficacy of drug therapy," he said.